secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2026-09-02T20:50:24+00:00
Accession:  0001829126-26-009659
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin SVP Quality/Regulatory/Clinical Carolyn Shelton departs; separation terms set
--------------------------------------------------------------------------------

- Carolyn Shelton departed as SVP of Quality, Regulatory, and Clinical Affairs on Aug 28, 2026.
- Separation agreement includes one month of base salary and a $20,000 2026 bonus.
- Unvested stock options accelerated; vested options exercisable for up to two years.
- Health insurance premiums subsidized through Sept 30, 2026; includes release of claims and confidentiality/non-disparagement/cooperation.
- Agreement to be filed as exhibit to next periodic report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626009659/0001829126-26-009659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626009659/nexalintec_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-009659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer